Keywords: Teva Pharma, Synribo, CML, Leukemiiua, USA, FDA, Novartis, Gleevec, atent expiry, Tasigna switching
FDA approves Teva's Synribo for CML; Novartis plans for Tasigna switch
Article | 29 October 2012
The US Food and Drug Administration on Friday approved Israel-headquartered Teva Pharmaceutical Industries’ (NYSE: TEVA) Synribo (omacetaxine mepesuccinate) to ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
